Hyperhomocysteinemia in chronic renal failure
Keywords:
homocysteine, hyperhomocysteinemia, kidney failure, chronicAbstract
Homocysteine is a sulfur-containing amino acid derived from the metabolism of methionine, whose abnormal
accumulation in plasma is a risk factor for vascular disease in the general population and in patients with
chronic renal disease. In these patients, the prevalence of individuals with hyperhomocysteinemia is very high,
even in the pre-dialysis stage of the disease. The main factor that seems to be implicated on the elevation of
homocysteine levels in this population is the renal mass loss, considering that the kidney has an important
role in the metabolism of such amino acid. The treatment of hyperhomocysteinemia consists on supplementation of the vitamins that are involved in the homocysteine metabolism (folate, B6 and B12). However, for chronic renal disease patients, this treatment is not completely effective, because although it promotes reduction of homocysteine levels, the normalization is not reached in the majority of the patients. This study reviews the hyperhomocysteinemia etiology on chronic renal disease, its main determinants, its relationship with vascular diseases, and the modes of treatment.
References
Chauveau P, Chadefaux B, Coude M, Aupetit J, Hannedouche T, Kamoun P, et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int. 1993; 41:S72-7.
Bostom AG, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int. 1997; 52(1):10-20.
Dennis V, Robinson K. Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int. 1996; 50:S11-7.
Blom HJ, De Vriese S. Why are homocysteine levels increased in kidney failure? A metabolic approach. J Lab Clin Med. 2002; 139(5):262-8.
Mangoni AA, Jackson SHD. Homocysteine and cardiovascular disease: Current evidence and future prospects. Am J Med. 2002; 112(7):556-65.
Audelin MC, Genest Jr J. Homocysteine and cardiovascular disease in diabetes mellitus. Atherosclerosis. 2001; 159(2):497-511.
Arruda VR, Siqueira LH, Gonçalves MS, von Zuben PM, Soares MC, Menezes R, et al. Prevalence of the mutation C677à T in the methylene tetrahydrofolate reductase gene among distinct ethnic groups in Brazil. Am J Med Genet. 1998; 78(4):332-5.
Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Mathews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995; 10(1):111-3.
De Bree A, Verschuren WMM, Blom HJ, Kromhout D. Lifestyle factors and plasma homocysteine concentrations in a general population sample. Am J Epidemiol. 2001; 154(2):150-4.
Jackes PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am J Clin Nutr. 2001; 73(3): 613-21.
Mennen LI, de Couray GP, Guilland JC, Ducros V, Bertrais S, Nicolas JP, et al. Homocysteine, cardiovascular disease risk factors, and habitual diet in the French Supplementation with Antioxidant Vitamins and Minerals Study. Am J Clin Nutr. 2002; 76(6):1279-89.
Welch GH, Loscalzo J. Homocysteine and atherothrombosis. N Eng J Med. 1998; 338(15): 1042-50.
Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med. 1991; 324(17):1149-55.
Perna AF, Ingrosso D, Satta E, Romano M, Cimmino A, Galletti P, et al. Metabolic consequences of hyperhomocysteinemia in uremia. Am J Kidney Dis. 2001; 38(4 Suppl 1):S85-90.
Moustapha A, Grupta A, Robinson H, Arheart K, Jacobson DW, Schreiber MJ, et al. Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. Kidney Int. 1999; 55(4):1470-5.
Jungers P, Joly D, Chauveau P, Nguyen AT, Aupetit J, Chadefaux, B. Sustained reduction of hyperhomocysteinemia with folic acid supplementation in predialysis patients. Nephrol Dial Transplant. 1999; 14(12):2903-6.
Hultberg B, Andersson A, Sterner G. Plasma homocysteine in renal failure. Clin Nephrol. 1993; 40(4):230-4.
Suliman ME, Qureshi AR, Barany P, Stenvinkel P, Filho JC, Anderstam B, et al. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int. 2000; 57(4): 1727-35.
Jungers P, Massy ZA, Khoa TN, Fumeron C, Labrunie M, Lacour B, et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. Nephrol Dial Tranplant. 1997; 12(12):2597-602.
Suliman ME, Stenvinkel P, Heimbürger O, Bàràny P, Lindholm B, Bergström J. Plasma sulfur amino acids in relation to cardiovascular disease, nutritional status, and diabetes mellitus in patients with chronic renal failure at start of dialysis therapy. Am J Kidney Dis. 2002; 40(3):480-8.
Malamaci F, Zoccali C, Tripepi G, Ferme I, Benedetto FA, Cataliotti A, et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int. 2002; 61(2):609-14.
Robinson K, Grupta A, Dennis V, Arheart K, Chaudhary D, Green R, et al. Hyperhomocysteinemia confers an independent increase risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation. 1996; 94(11): 2743-78.
Wollesen F, Brattström L, Refsum H, Ueland PM, Berglund L, Berne C. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int. 1999; 55(3):1028-35.
Arnadottir M, Hultberg B, Nilsson-Ehle P, Thysell H. The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Lab Invest. 1996; 56(1):41-6.
Wrone EM, Zehnder JL, Hornberger JM, McCann LM, Coplon NS, Fortmann SP. An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease. Kidney Int. 2001; 60(3):1106-13.
Morimoto K, Haneda T, Okamoto K, Ishida H, Kikuchi K. Methylenetetrahydrofolate reductase gene polymorphism, hyperhomocysteinemia, and cardiovascular diseases in chronic hemodialysis patients. Nephron. 2002; 90(1):43-50.
Dierkes J, Domröse U, Bosselmann HP, Neumann KH, Luley C. Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease. Clin Nephrol. 1999; 51(2):108-15.
Guttormsen AB, Ueland PM, Svarstad E, Refsum H. Kinetcs basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int. 1997; 52(2):495-502.
Van Guldener C, Kulik W, Berger R, Dijkstra DA, Jackobs C, Reyngoud DJ, et al. Homocysteine and methionine metabolism in ESRD: A stable isotope study. Kidney Int. 1999; 56(3):1064-71.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Fabiana Baggio NERBASS, Sérgio Antonio DRAIBE, Lilian CUPPARI
This work is licensed under a Creative Commons Attribution 4.0 International License.
